Bibliography
- Vakil N, Van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101(8):1900-20
- Dent J, El-Serag HB, Wallander MA, et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005;54(5):710-7
- Kahrilas PJ. Clinical practice. Gastroesophageal reflux disease. N Engl J Med 2008;359(16):1700-7
- Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006;55(10):1398-402
- Savarino E, Pohl D, Zentilin P, et al. Functional heartburn has more in common with functiional dyspapsia than with non-erosive reflux disease. Gut 2009. In press
- Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112(6):1798-810
- Lindberg P, Brandstrom A, Wallmark B, et al. Omeprazole: the first proton pump inhibitor. Med Res Rev 1990;10(1):1-54
- Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000;118(4):661-9
- Gralnek IM, Dulai GS, Fennerty MB, et al. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol 2006;4(12):1452-8
- Edwards SJ, Lind T, Lundell L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis – a comparison of esomeprazole with other PPIs. Aliment Pharmacol Ther 2006;24(5):743-50
- Savarino V, Di MF, Scarpignato C. Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety. Pharmacol Res 2009;59(3):135-53
- Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov 2003;2(2):132-9
- Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995;333(17):1106-10
- Netzer P, Schmitt B, Inauen W. Effects of ABT-229, a motilin agonist, on acid reflux, oesophageal motility and gastric emptying in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002;16(8):1481-90
- Fass R, Shapiro M, Dekel R, et al. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease–where next? Aliment Pharmacol Ther 2005;22(2):79-94
- Bredenoord AJ, Smout AJ. Refractory gastrooesophageal reflux disease. Eur J Gastroenterol Hepatol 2008;20(3):217-23
- Sachs G, Shin JM, Briving C, et al. The pharmacology of the gastric acid pump: the H+,K+ ATPase. Annu Rev Pharmacol Toxicol 1995;35:277-305
- Kahrilas PJ, Sifrim D. High-resolution manometry and impedance-pH/manometry: valuable tools in clinical and investigational esophagology. Gastroenterology 2008;135(3):756-69
- Vela MF, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001;120(7):1599-606
- Fass R. Persistent heartburn in a patient on proton-pump inhibitor. Clin Gastroenterol Hepatol 2008;6(4):393-400
- Ang D, Sifrim D, Tack J. Mechanisms of heartburn. Nat Clin Pract Gastroenterol Hepatol 2008;5(7):383-92
- Sharma P, Shaheen NJ, Perez MC, et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation–results from two randomized controlled studies. Aliment Pharmacol Ther 2009;29(7):731-41
- Metz DC, Howden CW, Perez MC, et al. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther 2009;29(7):742-54
- Metz DC, Vakily M, Dixit T, et al. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther 2009;29(9):928-37
- Periclou AP, Goldwater R, Lee SM, et al. A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease. Clin Pharmacol Ther 2000;68(3):304-11
- Domagala F, Ficheux H, Houin G, et al. Pharmacokinetics of tenatoprazole, a newly synthesized proton pump inhibitor, in healthy male Caucasian volunteers. Arzneimittelforschung 2006;56(1):33-9
- Thomson AB, Cohen P, Ficheux H, et al. Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study. Aliment Pharmacol Ther 2006;23(8):1179-87
- Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther 2005;108(3):294-307
- Asano S, Yoshida A, Yashiro H, et al. The cavity structure for docking the K(+)-competitive inhibitors in the gastric proton pump. J Biol Chem 2004;279(14):13968-75
- Nilsson C, Albrektson E, Rydholm H, et al. Tolerability, pharmacokinetics and effects on gastric acid secretion after single oral doses of the potassium-competitive acid blocker AZD0865 in healthy male subjects [abstract]. Gastroenterology 2009;128(4 Suppl 2):A528
- Yu KS, Bae KS, Shon JH, et al. Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers. J Clin Pharmacol 2004;44(1):73-82
- Dent J, Dodds WJ, Friedman RH, et al. Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. J Clin Invest 1980;65(2):256-67
- Holloway RH, Penagini R, Ireland AC. Criteria for objective definition of transient lower esophageal sphincter relaxation. Am J Physiol 1995;268(1 Pt 1):G128-33
- Boeckxstaens GE. The lower oesophageal sphincter. Neurogastroenterol Motil 2005;17(Suppl 1):13-21
- Mittal RK, Holloway R, Dent J. Effect of atropine on the frequency of reflux and transient lower esophageal sphincter relaxation in normal subjects. Gastroenterology 1995;109(5):1547-54
- Lehmann A. GABA(B) receptors as drug targets to treat gastroesophageal reflux disease. Pharmacol Ther 2009;122(3):239-45
- McDermott CM, Abrahams TP, Partosoedarso E, et al. Site of action of GABA(B) receptor for vagal motor control of the lower esophageal sphincter in ferrets and rats. Gastroenterology 2001;120(7):1749-62
- Lehmann A, Antonsson M, Bremner-Danielsen M, et al. Activation of the GABA(B) receptor inhibits transient lower esophageal sphincter relaxations in dogs. Gastroenterology 1999;117(5):1147-54
- Lidums I, Lehmann A, Checklin H, et al. Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology 2000;118(1):7-13
- Zhang Q, Lehmann A, Rigda R, et al. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut 2002;50(1):19-24
- Vela MF, Tutuian R, Katz PO, et al. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003;17(2):243-51
- Koek GH, Sifrim D, Lerut T, et al. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003;52(10):1397-402
- Castell D, Gerson LB, Hirota WK, et al. R-Baclofen prodrug Xp19986 decreases reflux episodes and is well tolerated in GERD patients [abstract]. Gastroenterology 2008;132(4 Suppl 1):A-486
- Lehmann A, Elebring T, Jensen J, et al. In vivo and in vitro characterization of AZD9343, a novel GABAB receptor agonist and reflux inhibitor [abstract]. Gastroenterology 2008;134(4):A-131-2
- Lehmann A, Branden L, Carlsson A, et al. AZD3355, a novel GABAB receptor agonist inhibits transient lower esophageal sphincter relaxation in the dog. [abstract]. Gastroenterology 2008;134(4):A-49-50
- Boeckxstaens GE, Beaumont H, Rydholm H, et al. Effect of the GABAB receptor agonist AZD9343 on transient lower esophageal sphincter relaxations and acid reflux in healthy subjects: a phase I trial. [abstract]. Gastroenterology 2008;134(4):A-126
- Boeckxstaens GE, Rydholm H, Adler JRM. Effect of AZD3355, a novel GABA B receptor agonist, on transient lower esophageal sphincter relaxations in healthy volunteers [abstract]. Gastroenterology 2009;136(Suppl 1):772
- Page AJ, Young RL, Martin CM, et al. Metabotropic glutamate receptors inhibit mechanosensitivity in vagal sensory neurons. Gastroenterology 2005;128(2):402-10
- Jensen J, Lehmann A, Uvebrant A, et al. Transient lower esophageal sphincter relaxations in dogs are inhibited by a metabotropic glutamate receptor 5 antagonist. Eur J Pharmacol 2005;519(1-2):154-7
- Frisby CL, Mattsson JP, Jensen JM, et al. Inhibition of transient lower esophageal sphincter relaxation and gastroesophageal reflux by metabotropic glutamate receptor ligands. Gastroenterology 2005;129(3):995-1004
- Knowles CH, Aziz Q. Visceral hypersensitivity in non-erosive reflux disease. Gut 2008;57(5):674-83
- Matthews PJ, Aziz Q, Facer P, et al. Increased capsaicin receptor TRPV1 nerve fibres in the inflamed human oesophagus. Eur J Gastroenterol Hepatol 2004;16(9):897-902
- Hunt RH, Armstrong D, Yaghoobi M, et al. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment Pharmacol Ther 2008;28(2):187-99
- Galmiche JP, Sacher-Huvelin S, Bruley des Varannes, et al. A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers. Aliment Pharmacol Ther 2005;21(5):575-82
- Hunt RH, Armstrong D, James C, et al. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am J Gastroenterol 2005;100(9):1949-56
- Mori H, Tonai-Kachi H, Ochi Y, et al. N-(2-hydroxyethyl)-N, 2-dimethyl-8-{[(4R)-5-methyl-3, 4-dihydro-2H-chromen-4 -yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease. J Pharmacol Exp Ther 2009;328(2):671-9
- Kahrilas PJ, Dent J, Lauritsen K, et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 2007;5(12):1385-91
- Dent J, Kahrilas PJ, Hatlebakk J, et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol 2008;103(1):20-6
- Vakil NB, Huff FJ, Bian A, et al. Arbaclofen placarbil monotherapy decreases GERD symptoms in subjects with previous PPI therapy. [abstract]. Gastroenterology 2009;136(Suppl 1):490
- Boeckxstaens GE, Beaumont H, Hatlebakk J, et al. Efficacy and tolerability of the novel reflux inhibitor AZD3355 as add-on treatment in GERD patietns with symptoms despite proton pump inhibitor therapy [abstract]. Gastroenterology 2009;136(Suppl 1):M1875
- Hirsch DP, Tytgat GN, Boeckxstaens GE. Is glutamate involved in transient lower esophageal sphincter relaxations? Dig Dis Sci 2002;47(3):661-6
- Keywood C, Wakefield M, Tack J. A proof of concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastroesophageal reflux disease. Gut 2009. In press
- Zerbib F, Keywood C. Efficacy and tolerability of ADX10059, a negative allosteric modulator of mGluR5, on gastroesophageal reflux: a pH-impedance study in healthy subjects [abstract]. Gastroenterology 2009;136(Suppl 1):M1867
- Beaumont H, Boeckxstaens GE. Does the presence of a hiatal hernia affect the efficacy of the reflux inhibitor baclofen during add-on therapy? Am J Gastroenterol 2009;104(7):1764-71